| Target Audience: |
|
Licensed Massachusetts primary care physicians and nurse practitioners
|
| Course Director: |
|
Ellliot Sternthal, MD
Assistant Professor of Medicine
Boston University School of Medicine
Director of Outpatient Diabetes Program
Boston Medical Center
|
| Educational Needs Addressed: |
|
It is well-known that Type 2 Diabetes is on the verge of becoming an epidemic in the United States. To further complicate the treatment of this disease is an inadequate and decreasing number of endocrinologists. Experts suggest that the number of practicing endocrinologists accounts for less than 12% of the number of endocrinologists needed for proper treatment of diabetes, leaving the treatment and management of Type 2 Diabetes and all of its comorbidities to primary care clinicians. This Diabetes Preceptorship is designed to give you, the primary care clinician the hands-on training and confidence necessary to effectively treat your diabetic patients.
|
| Educational Objectives: |
|
At the conclusion of this activity, participants will be able to:
| 1) |
Recognize the multiple pathophysiologic components of Type 2 Diabetes
|
| 2) |
Develop strategies for assessment, treatment, and follow-up to minimize complications of Type 2 Diabetes
|
| 3) |
Evaluate and integrate evolving therapies into day-to-day clinical practice so that primary care physicians can take on a more prominent role in the management of Type 2 Diabetes
|
|
| Accreditation: |
|
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this educational activity for a maximum of 26.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians may self-claim an additional 8 AMA PRA Category 2 Credits™.
|
| Grant Support: |
|
This activity is supported in part by unrestricted educational grants from Merck, Pfizer, and Sanofi Aventis.
|
